Replimune Group, Inc. 8K

Replimune announced FDA accelerated approval and near-term U.S. launch of TUDRIQEV for advanced melanoma, strengthened its cash position via a $150 million financing to fund commercialization and trials, and appointed a new Chief Commercial Officer while reporting fiscal Q1 2027 results and a narrowed net loss.

On August 14, 2026, Replimune Group, Inc. reported financial results for its fiscal first quarter ended June 30, 2026 and provided a corporate update highlighting that the FDA granted accelerated approval to TUDRIQEV (vusolimogene oderparepvec-wtpg, formerly RP1) in combination with nivolumab for adults with unresectable advanced cutaneous melanoma progressing on PD-1–based therapy, with U.S. commercial launch expected within 60 days; the company also disclosed completion of a $150 million equity financing that, together with existing cash and equivalents of $195.3 million as of June 30, 2026 and $141.0 million of August 2026 equity proceeds, extends its cash runway beyond twelve months to support TUDRIQEV commercialization and the IGNYTE-3 confirmatory trial, and announced the appointment of Michelle DiNapoli as Chief Commercial Officer effective August 18, 2026, while reporting reduced R&D and SG&A expenses and a narrower net loss of $69.8 million versus the prior-year quarter.

Filing Facts

CIK

1737953

Ticker

REPL

Form

8K

Source Type

fda

Accession

0001104659-26-096483

Alert Tier

8